A new bead‐based human platelet antigen antibodies detection assay versus the monoclonal antibody immobilization of platelet antigens assay

Abstract

For the vast majority of the specimens tested (93%) the results of the PAKLx were in concordance with the MAIPA. The PAKLx is a fast, easy to perform, and sensitive PLT antibody screening method.

Current perspectives on fetal and neonatal alloimmune thrombocytopenia – increasing clinical concerns and new treatment opportunities

“…Other techniques are also possible to use. For instance, different Luminex bead-based assays for the detection of anti-HPA-1a antibodies have been tested and are used by some 62. Furthermore, low-avidity anti-HPA-1a antibodies may be detected using surface plasmon resonance technology 63…”

Detection and identification of platelet antibodies using a sensitive multiplex assay system–platelet antibody bead array

“…Recently, the performance of a commercial, bead‐based ACE assay, PAKLx, was compared with the MAIPA by two groups . PAKLx design differs from the PABA, in that beads are supplied with individual platelet GPs already captured by specific monoclonal antibodies, and patient sera are simply incubated with the bead mixture for platelet antibody detection.…”

“…Recently, several different antigen‐capture assays for the detection of platelet antibodies have been reported that use polystyrene beads instead of wells of polystyrene microplates to capture platelet GPs, including a bead version of the MAIPA and a commercial bead version of the ACE . We have now developed the platelet antibody bead array (PABA), which is a bead version of the MACE but with a fluorescent antibody detection endpoint instead of ELISA.…”

Screening for fetal and neonatal alloimmune thrombocytopenia: is it possible and what are the potential outcomes?

“…Women carrying an HPA‐1a‐positive fetus should be examined for HPA‐1a antibodies at regular intervals during pregnancy, for instance every 4–6 weeks. Examination for anti‐HPA‐1a antibodies has until recently been technically challenging, but this analysis can today be performed easily using a newly developed bead‐based platelet antibody‐detecting assay (Pak Lx™, Immucor) . Women with HPA‐1a antibodies should be referred to a specialized centre for maternal‐fetal medicine for close follow‐up and risk stratification.…”